FDA Drug recall D-0450-2022
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05
- FDA Drug
- Class II
- terminated
- Published 2022-02-02
On 2022-02-02 the FDA classified a Class II recall of Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05 by Aurobindo Pharma Usa, citing superpotent and Failed Tablet/Capsule Specifications.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0450-2022 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2021-12-29 |
| Published | 2022-02-02 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Aurobindo Pharma Usa |
| Distribution | US |
Product
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05
Reason
Superpotent and Failed Tablet/Capsule Specifications
Identifiers
| ndc | 57237-219-30 |
|---|---|
| ndc | 57237-219-90 |
| ndc | 57237-219-05 |
| ndc | 57237-220-30 |
| ndc | 57237-220-90 |
| ndc | 57237-220-05 |
| ndc | 57237-221-30 |
| ndc | 57237-221-90 |
| ndc | 57237-221-05 |
| code_info | Batch # PF4520028B & PF4520028A, Exp. Date 11/2022 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0450-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.